2/13/2021

speaker
Jerry Sususki
Chief Executive Officer

Aloha from Kona, Hawaii. Thank you all for joining us today to report Cyanotech's third quarter fiscal year 2021 earnings results. I am Jerry Sususki, Chief Executive Officer of Cyanotech. Joining me on the call today is Felicia Layden, our Chief Financial Officer. I will turn the call over to Felicia to provide our forward-looking statement.

speaker
Felicia Layden
Chief Financial Officer

Thanks, Jerry. Our discussion today may include forward-looking statements. We do not undertake any obligation to update forward-looking statements either as a result of new information, future events, or otherwise. Our actual results may differ materially from what is described in these forward-looking statements. Some of the factors that may cause results to differ are listed in our publicly filed documents. For additional information, we encourage you to review our 10Q in fiscal year 2020 report filed with the Securities and Exchange Commission. I will turn it back to Jerry for comments on the quarter. Jerry?

speaker
Jerry Sususki
Chief Executive Officer

The company's third quarter results were negatively impacted by two factors. The timing of products received by our customers from our carriers and the higher cost of sales. Overall, we are continuing to see positive trends in the sales of our e-commerce business as consumers shift their shopping preference to online during a global pandemic. Our gross margins this quarter were lower than the same quarter prior year and are trend in the current fiscal year as a result of sales of higher cost inventory for astaxanthin produced in FY 2020 during the winter months where yields are typically lower as a result of fewer hours and lower intensity sunlight. In addition, the current quarter was also impacted by higher current year spirulina costs per kilo driven by lower production. During the quarter, we received full forgiveness from the Small Business Administration on the $1.389 million Paycheck Protection Program loan, including accrued interest of $8,000. We paid $250,000 on the line of credit. Now turning over to Felicia to discuss the financial results. Felicia?

speaker
Felicia Layden
Chief Financial Officer

Thanks, Jerry. Key financial results for the third quarter. Total net sales for the third quarter of fiscal 2021 were $6,895,000 compared to $7,504,000 for the third quarter of fiscal 2020. Total sales revenue decreased by $519,000, or 7% from prior year. The biggest driver of the overall sales decrease was the timing of customer shipments. Nutrex sales declined by $1,344,000 or 21%, offset by higher sales of bulk product of $714,000 or 72%. Gross profit for the third quarter of fiscal 2021 was $2,071,000 with gross profit margin of 29.6%. compared to gross profit of $2,877,000 and gross profit margin of 38.3% in the third quarter of fiscal 2020. The 8.7 percentage point decline was previously discussed. Operating loss for the quarter was $441,000 compared to operating income of $367,000 in the third quarter of fiscal 2020. Net income was $827,000, or 13 cents per diluted share, compared to a net income of $171,000, or 3 cents per diluted share, with the increase primarily due to the forgiveness of the loan under the Paycheck Protection Program in the amount of $1,389,000, including accrued interest of $8,000.00. The company had cash of $3.3 million and working capital of $8.4 million as compared to $2.4 million and $8.4 million respectively as of March 31, 2020. I will hand the call back to Jerry for concluding comments. Jerry?

speaker
Jerry Sususki
Chief Executive Officer

We have not had any questions. Thank you all for attending the call. Please stay safe and healthy. Aloha.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-